PT  - JOURNAL ARTICLE
AU  - Hunt, Danielle T.
AU  - Yates, Jennifer L.
AU  - Kulas, Karen E.
AU  - Carson, Kyle
AU  - Lamson, Theresa
AU  - Demarest, Valerie
AU  - Furuya, Andrea
AU  - Howard, Kelly
AU  - Marchewka, Mary
AU  - Stone, Randy
AU  - Tucker, Heidi
AU  - Warszycki, Casey
AU  - Yee, Jim
AU  - Yang, He S.
AU  - Racine-Brzostek, Sabrina
AU  - Zhao, Zhen
AU  - Ejemel, Monir
AU  - Li, Qi
AU  - Wang, Yang
AU  - Fernando, Sebastian
AU  - La Carpia, Francesca
AU  - Hod, Eldad A.
AU  - McDonough, Kathleen A.
AU  - Lee, William T.
TI  - COVID-19 Serology in New York State Using a Multiplex Microsphere Immunoassay
AID  - 10.1101/2021.05.12.21257125
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.12.21257125
4099  - http://medrxiv.org/content/early/2021/05/15/2021.05.12.21257125.short
4100  - http://medrxiv.org/content/early/2021/05/15/2021.05.12.21257125.full
AB  - The emergence of SARS-CoV-2, leading to COVID-19, necessitated the development of new molecular and serological tests. Here, we describe a multiplexed serological assay developed as the global pandemic moved into New York State in the spring of 2020. The original microsphere immunoassay used a target antigen from the SARS-CoV-1 virus responsible for the 2003 SARS outbreak, but evolved to incorporate multiple SARS-CoV-2 protein antigens (nucleocapsid, spike and spike domains, spike and nucleocapsid proteins from seasonal human coronaviruses). Besides being highly versatile due to multiplex capabilities, the assay was highly specific and sensitive and adaptable to measuring both total antibodies and antibody isotypes. While determining the assay performance characteristics, we were able to identify antibody production patterns (e.g., kinetics of isotypes, individual variations) for total antibodies and individual antibody classes. Overall, the results provide insights into the laboratory response to new serology needs, and how the evolution and fine-tuning of a serology assay helped contribute to a better understanding of the antibody response to SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was performed in part under a Project Award Agreement from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance award 70NANB20H037 from the U.S. Department of Commerce, National Institute of Standards and Technology. Additional support was provided by a grant (P20-000271) from the New York Community Trust. A portion of the work described in this publication was supported by Cooperative Agreement Number NU50CK000516 from the Centers of Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All testing and archiving of human specimens were done under a declared New York State Public Health Emergency and also approved by New York State Department of Health Institutional Review Board (IRB 20-021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this submitted article (and its supplementary information files)1AbbreviationsCOVID-19coronavirus disease 2019SARS-CoV-2Severe acute respiratory syndrome coronavirus 2HuCOVhuman endemic (seasonal) coronavirusesAbantibodyDILDiagnostic Immunology Laboratory at the Wadsworth CenterNnucleocapsid proteinRBDreceptor-binding domainMFImedian fluorescent intensityFDAFood and Drug AdministrationEUAEmergency Use AuthorizationMIAmicrosphere immunoassay